Esperion Therapeutics (ESPR) Short term Debt (2014 - 2018)

Esperion Therapeutics has reported Short term Debt for 5 years, with the latest figure at $152000.0 in Q2 2018.

• For the quarter ending Q2 2018, Short term Debt fell 91.38% year-over-year to $152000.0; the trailing twelve-month figure through Jun 2018 stood at $152000.0 (down 91.38% YoY), and the FY2017 full-year result was $1.0 million, down 38.85% from the prior year.
• Short term Debt for Q2 2018 stood at $152000.0, down from $603000.0 in the prior quarter.
• The five-year high for Short term Debt was $1.8 million in Q2 2017, with the low at $152000.0 in Q2 2018.
• Historically, Short term Debt has averaged $1.2 million across 5 years, with a median of $1.5 million in 2015.
• Annual changes were most pronounced in 2015 — Short term Debt soared 523.72% — and 2018, when it plunged 91.38%.
• Esperion Therapeutics' Short term Debt stood at $638000.0 in 2014, then soared by 151.41% to $1.6 million in 2015, then rose by 6.55% to $1.7 million in 2016, then slumped by 38.85% to $1.0 million in 2017, then slumped by 85.45% to $152000.0 in 2018.
• The last three Short term Debt figures came in at $152000.0 (Q2 2018), $603000.0 (Q1 2018), and $1.0 million (Q4 2017), per Business Quant data.